Condition: Myotonic Dystrophy Type 1 (DM1) · Sponsor: Dyne Therapeutics
The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (168 weeks) in both multiple-ascending dose (MAD) and dose expansion cohorts.
This description comes directly from the study's public registry record.
Dyne Clinical Trials · +1-781-317-1919 · clinicaltrials@dyne-tx.com
Always discuss trial participation with your own doctor first.
| Stanford University | Stanford, California, United States | Recruiting |
| University of Florida College of Medicine | Gainesville, Florida, United States | Recruiting |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
| Neurology Rare Disease Center | Denton, Texas, United States | Recruiting |
| Virginia Commonwealth University (VCU) | Richmond, Virginia, United States | Recruiting |
| St. Vincent's Hospital | Fitzroy, Victoria, Australia | Recruiting |
| CHU de Nantes | Nantes, France | Recruiting |
| Institut de Myologie | Paris, France | Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05481879